Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia

JCI Insight

Volumn 2, Issue 20, 2017, Pages

  Jourdain, Vincent A ^a   Schindlbeck, Katharina A ^a   Tang, Chris C ^a   Niethammer, Martin ^a,b   Choi, Yoon Young ^a   Markowitz, Daniel ^c   Nazem, Amir ^a   Nardi, Dominic ^b   Carras, Nicholas ^b   Feigin, Andrew ^a,b   Ma, Yilong ^a   Peng, Shichun ^a   Dhawan, Vijay ^a   Eidelberg, David ^a,b  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b Northwell Health   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85034845409     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.96411     Document Type: Article

References (33)

1. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol. 2006;63(2):205–209.
2. Cenci MA. Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications. Front Neurol. 2014;5:242.
3. Hirano S, et al. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson’s disease. J Neurosci. 2008;28(16):4201–4209.
4. Jourdain VA, et al. Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia. JCI Insight. 2016;1(15):e86615.
5. Ohlin KE, Sebastianutto I, Adkins CE, Lundblad C, Lockman PR, Cenci MA. Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson’s disease. Neuroimage. 2012;61(1):228–239.
6. Lerner RP, et al. Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model. Neurobiol Dis. 2016;96:31–37.
7. Edvinsson L, Krause D. Catecholamines. In: Edvinsson L, Krause D, eds. Cerebral Blood Flow and Metabolism. Philadelphia, PA: Lippincott Williams & Wilkins;2002:191–211.
8. Choi JK, Chen YI, Hamel E, Jenkins BG. Brain hemodynamic changes mediated by dopamine receptors: Role of the cerebral microvasculature in dopamine-mediated neurovascular coupling. Neuroimage. 2006;30(3):700–712.
9. Afonso-Oramas D, et al. Striatal vessels receive phosphorylated tyrosine hydroxylase-rich innervation from midbrain dopaminergic neurons. Front Neuroanat. 2014;8:84.
10. Rocher AB, Chapon F, Blaizot X, Baron JC, Chavoix C. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage. 2003;20(3):1894–1898.
11. Patel AB, et al. Direct evidence for activity-dependent glucose phosphorylation in neurons with implications for the astrocyte-to-neuron lactate shuttle. Proc Natl Acad Sci USA. 2014;111(14):5385–5390.
12. Lindgren HS, Ohlin KE, Cenci MA. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson’s disease. Neuropsychopharmacology. 2009;34(12):2477–2488.
13. Westin JE, et al. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci. 2006;26(37):9448–9461.
14. Desai Bradaric B, Patel A, Schneider JA, Carvey PM, Hendey B. Evidence for angiogenesis in Parkinson’s disease, incidental Lewy body disease, and progressive supranuclear palsy. J Neural Transm (Vienna). 2012;119(1):59–71.
15. Janelidze S, et al. Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology. 2015;85(21):1834–1842.
16. Ohlin KE, et al. Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain. 2011;134(Pt 8):2339–2357.
17. Vogel J, Gehrig M, Kuschinsky W, Marti HH. Massive inborn angiogenesis in the brain scarcely raises cerebral blood flow. J Cereb Blood Flow Metab. 2004;24(8):849–859.
18. Ben Bashat D, et al. Hemodynamic response imaging: a potential tool for the assessment of angiogenesis in brain tumors. PLoS ONE. 2012;7(11):e49416.
19. García-Cabezas MA, Rico B, Sánchez-González MA, Cavada C. Distribution of the dopamine innervation in the macaque and human thalamus. Neuroimage. 2007;34(3):965–984.
20. Iadecola C. Does nitric oxide mediate the increases in cerebral blood flow elicited by hypercapnia? Proc Natl Acad Sci USA. 1992;89(9):3913–3916.
21. Wang Q, Pelligrino DA, Baughman VL, Koenig HM, Albrecht RF. The role of neuronal nitric oxide synthase in regulation of cerebral blood flow in normocapnia and hypercapnia in rats. J Cereb Blood Flow Metab. 1995;15(5):774–778.
22. Cilia R, et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(Pt 10):2731–2742.
23. Huang C, et al. Changes in network activity with the progression of Parkinson’s disease. Brain. 2007;130(Pt 7):1834–1846.
24. Ishikawa T, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDO-PA/PET. J Nucl Med. 1996;37(11):1760–1765.
25. Kazumata K, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998;39(9):1521–1530.
26. Tang CC, Poston KL, Dhawan V, Eidelberg D. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson’s disease. J Neurosci. 2010;30(3):1049–1056.
27. Adair TH, Montani JP. Angiogenesis. In: Granger DN, Granger JP, eds. Colloquium Series on Integrated Systems Physiology: From Molecule to Function to Disease. San Rafael, CA: Morgan & Claypool Life Sciences;2010. https://www.ncbi.nlm.nih.gov/books/NBK53242/.
28. Niethammer M, Eidelberg D. Metabolic brain networks in translational neurology: concepts and applications. Ann Neurol. 2012;72(5):635–647.
29. Holtbernd F, et al. Dopaminergic correlates of metabolic network activity in Parkinson’s disease. Hum Brain Mapp. 2015;36(9):3575–3585.
30. Teema AM, Zaitone SA, Moustafa YM. Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis. Neuropharmacology. 2016;107:432–450.
31. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr. 1992;55(3):181–184.
32. Yezhuvath US, Lewis-Amezcua K, Varghese R, Xiao G, Lu H. On the assessment of cerebrovascular reactivity using hypercapnia BOLD MRI. NMR Biomed. 2009;22(7):779–786.
33. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–2653.